Compare AbCellera Biologics Inc (ABCL) vs Carlyle Group Inc (CG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Carlyle Group Inc — how do they compare? AbCellera Biologics Inc trades at $9.11 (market cap $2.99B), while Carlyle Group Inc trades at $48.27 (market cap $17.23B). The key difference: Carlyle Group Inc is far larger — about 5.8× AbCellera Biologics Inc's market cap, and Carlyle Group Inc pays a 2.9% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | CG | |
|---|---|---|
Market Cap | $2.99B | $17.23B |
Sector | Health | Financials |
52-Week High | $9.76 | $69.35 |
52-Week Low | $2.78 | $40.52 |
Enterprise Value | $2.58B | — |
Dividend Yield | — | 2.9% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →
